Recurrence score may cut costs for high-risk breast cancer care

(HealthDay)—Genomic recurrence score (RS) testing using a 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer who would otherwise receive standard chemotherapy, according to a study published in the March issue of the Journal of the National Comprehensive Cancer Network.

* This article was originally published here